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SUMMARY 
Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are the most common cause of 
acquired weakness in intensive care units (ICU). However, its exact pathogenesis remains unclear. 
Abnormal excitability of muscle due to a sodium channelopathy is one of the mechanisms proposed. 
The aim of this study is to test for the presence of anti-ganglioside antibodies in serum from patients 
with CIM or both combined CIM/CIP, since there is evidence that they can cause reversible 
dysfunction of voltage-gated sodium channels. 
Methods: In a prospective way, we studied 35 patients admitted in ICU by weekly EMG. When positive 
spontaneous activity (PSA) was detected, a muscle biopsy was performed. Twenty patients met 
criteria of CIM; five of them also developed overlapping CIP. We did not detect any kind of 
abnormality in 10 patients during the follow up period. Sera were analyzed for the presence of anti-
ganglioside antibodies (Ganglioside-profile 2 Euroline, Euroimmun).  
Results: Overall, positive reactivity against anti-GT1b was found in one patient with CIM, representing 
2.8% (1/35) of the total sample. 
Conclusion: Reduced percentage of patients affected of CIM or CIM/CIP exhibits positive reactive 
against anti-ganglioside antibodies. Thus, it could be suggested they do not play a primary role in their 
pathogenesis. 
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INTRODUCTION 
Critical illness myopathy (CIM) and 
polyneuropathy (CIP) was first described in 
patients treated intensively for status 
asthmaticus with intravenous corticosteroids 
and neuromuscular junction-blocking agents(1) 
as well as in patients with sepsis and multiorgan 
failure who received assisted ventilation(2,3) Since 
then, they have been recognized as the most 
common cause of acquired weakness in critically 
ill patients(4) Its incidence is unkown so that it 
depends on different factors: specific intensive 
care unit subpopulation, diagnostic criteria used 
and time of diagnosis during the acute illness(5). 
There has been reported an incidence of 34-60% 
in patients with acute respiratory distress 
syndrome(6,7), 56-80% in those with multiorgan 
failure with or without sepsis or systemic 
inflammatory response syndrome (SIRS) and up 
to 100% in patients with septic shock(8). 
According to the previous data, severity of 
illness(9) and duration of multiple (≥two) organ 
dysfunction with or without SIRS(10,11) have been 
identified as independent risk factors in 
prospective studies. Duration of ICU stay, low 
serum albumin(12) and hyperglycaemia(13) have 
also been described as independent risk factors. 
CIM and CIP usually share the same clinical 
features. They present with limb and respiratory 
muscle weakness, frequently leading to a failure 
to wean from mechanical ventilation. Overall, 
both cause severe disability after critical illness, 
involving short and long term implications on 
the outcome of patients affected. CIP has been 
associated with increased duration of 
mechanical ventilation, length of ICU and 
hospital stay(14) Nearly a third of patients with 
CIP, CIM or both do not recover independent 
walking or spontaneous ventilation(15); 
furthermore, they are thought to be the leading 
cause of disability in patients who survive from 
acute respiratory distress syndrome(16) 
According to the findings from the 1-year 
follow-up in the CRIMYNE study, CIP might be 
the main contributor to persistent disability, 
while CIM should be associated with a faster 
recovery(17) Despite this striking impact on the 
outcome of critically ill patients, the exact 
pathogenesis of CIM and CIP is unknown. Data 
published until nowadays suggest that multiple 
pathophysiological mechanisms are involved. In 
the theater of a critically ill patient with a 
probable concomitant sepsis and under steroids 
and neuromuscular blocking agents, metabolic 
and hormonal (hyperglycemia and insulin 
resistance) disturbances developed leading to 
energetic failure. On the other hand, several 
studies provide experimental and clinical 
evidence of a dysfunction (hypoexcitability or 
inexcitability) of nerves(18,19) as well as muscle 
membrane(20,21,22) due to an acquired 
channelopathy with sodium channel 
inactivation(18,23,24,25,26) Circulating depolarization 
factor (CDF)(27) and an endotoxin that reduces 
muscle sodium channel availability at 
depolarized membrane potentials(28) have been 
proposed as etiopathogenic agents(27,28) 
The relationship between anti-glycolipid 
antibodies and acute neuropathy has been 
studied since late nineties(29). It has been 
demonstrated that ganglioside GM1 is enriched 
in nodal and paranodal structures, where it has 
regional co-localization with sodium and 
potassium channels(30). Furthermore, autopsy 
studies of AMAN cases have shown 
immunoglobulin and complement deposits 
localized at the node of Ranvier where sodium 
channels are clustered, and at the internodal 
axolemma(31) Electrophysiological studies on 
anti-GM1 antibody-mediated nerve injury have 
shown variable and divergent results; 
nonetheless, Takigawa et al. found that rabbit 
anti-GM1 antibodies increased potassium 
current elicited by step depolarization, and in 
the presence of active complement blocked 
sodium channels irreversibly(32). More recently, 
Weber et al. reported that IgG anti-GM1 
antibodies, raised in rabbits, could reversibly 
block the voltage-gated Na+ current, specially, 
in the presence of complement(33) From a clinical 
point of view, Kuwabara et al. measured indices 
of axonal excitability in patients with AMAN 
and AIDP; they found an increase of 
refractoriness in AMAN but not in AIDP 
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patients, which was reversible during four 
weeks period from onset(34).  
Taking into account that sepsis is one the main 
risk factor for CIM and CIP, relevant evidence 
concerning the carbohydrate mimicry between 
both human ganglioside GM1 and sodium 
channel and Campylobacter jejuni lipo-
oligosaccharide has been reported. Yuki et al. 
suggested that the carbohydrate mimicry 
between human ganglioside GM1 and 
Campylobacter jejuni lipo-oligosaccharide might 
be the cause of Guillain-Barré syndrome in 
certain patients(35). On the other hand, molecular 
mimicry between alfa subunit of Nav channel 
and Kdo2-Lipid A present in Campylobacter 
jejuni and other gram negative bacteria such E. 
Coli has been demonstrated(36). Usuki et al. found 
that sera from immunized chicken with anti-
ganglioside antibodies and anti-Kdo2-Lipid A 
could inhibite muscle voltage-gated Na (Nav1.4) 
channels by patch-clamp analysis(37). 
Previous data suggest that acute immune-
mediated neurophaties (mostly AMAN) share 
critical pathogenic features with CIP/CIM, and 
set the rationale base for this study, whose main 
goal is to test for the presence of anti-ganglioside 
antibodies in sera of patients diagnosed of 
CIM/CIP, as a first step to determine if they 
should play a role in their pathogenesis.  
PATIENTS AND METHODS 
The candidates for this prospective study were 
identified in daily screening log in the 
Department of Intensive Care Medicine, 
University Hospital Germans Trias i Pujol, 
Barcelona. Patients were eligible if they were at 
least 18 years old, presented a score ≥6 in the 
Sepsis-related Organ Failure Assessment (SOFA) 
index(38) while they were under mechanical 
ventilation and a stay in ICU longer than 2 
weeks. Exclusion criteria were documented 
history of prolonged immobility or 
neuromuscular disease and peripheral 
neurological (neuropathy, neuromuscular 
junction pathology or myopathy) or spinal cord 
disorders as reason of admission in the ICU. 
We obtained written informed consent from the 
surrogate decision maker within the four days 
after admission. Ethics approval was provided 
by the Ethics Committee of Hospital Universitari 
Germans Trias i Pujol.  
Apache II score was calculated in all patients at 
the moment of their admission in ICU(39) 
All patients included underwent an 
electrophysiological evaluation (5 channels 
Medelec Synergy equipment, Vyasis Healthcare, UK) 
at the moment of their inclusion and weekly 
during their stay in the ICU until they were 
extubated or died.  
Nerve conduction studies were performed from 
motor (median, peroneal and posterior tibial) 
and sensory (radial and sural) nerves using 
conventional procedures. Repetitive stimulation 
at 3 Hz (median nerve with recording from the 
abductor pollicis brevis or accessorius nerve 
with recording from the trapezius muscle) was 
done in all patients to screen for neuromuscular 
transmission defects. Coaxial needle 
electromyography of tibialis anterior, quadriceps 
and deltoids muscles was performed at multiple 
insertion points in order to detect pathological 
spontaneous activity (PSA) and to analyze motor 
unit potentials features, if the counsciousness 
level and degree of muscle weakness of the 
patient allowed their recording. 
When pathological spontaneous activity (PSA) 
was detected in the needle electromyographic 
study, a biopsy of the quadriceps muscle 
(Bergström needle) was performed within the next 
24-48 hours, whenever coagulation study and 
platelet count were normal. For electron 
microscopy evaluation, muscle biopsy 
specimens were fixed in glutaraldehyde, 
postfixed in osmium tetroxide and embedded in 
Epon. Thin sections were stained with uranil 
acetate and lead citrate and examined with 
transmission electron microscope (JEOL 1010). 
Although early fiber IIa atrophy and varying 
degrees of fiber necrosis have been described as 
signs of primary myopathy in CIM, selective loss 
of thick (myosin) filaments has been considered 
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as the main CIM diagnosis criteria from the 
histological point of view(40) (Figure 1)   
 
Figure 1: Uranil acetate stain electron  microscopy 
showing selective loss of thick myosin filaments 
CIP was diagnosed by electrophysiological 
criteria, when a complete loss of both SNAPs 
and CMAPs was detected. Muscular strength, 
according MRC scale, was measured one day 
immediately after cessation of mechanical 
ventilation and every month until normal 
muscular strength was achieved.  
Those patients without any kind of abnormality 
in electrophysiological studies performed during 
the follow-up period acted as a control group. 
Venous blood samples were extracted 
simultaneously with each EMG performed and 
the serum obtained was cryopreserved (-80ºC).  
Sera from both patients diagnosed of CIM, 
combined CIM and CIP and controls were tested 
for the presence of antibodies against 
gangliosides. We selected the serum sample 
obtained during the first EMG study where PSA 
was detected in CIM patients. In the control 
group, we chose the serum extracted two weeks 
after their admission, which represents the 
period with highest likelihood of CIM/CIP 
development (unpublished observations). 
All samples were analyzed by a qualitative 
method, Profile 2 Euroline, Euroimmun, (Lubeck, 
Germany). Most of antigen substrates used were 
from bovine brain, except the GM3 antigen that 
was from dog erythrocytes. This test specifically 
detects IgG and IgM class antibodies to GM1, 
GM2, GM3, GD1a, GD1b, GT1b and GQ1b. No 
cross reactions with other autoantibodies have 
been found. Interferences have not been 
demonstrated with haemolytic, lipaemic and 
icteric sera. The blot strips were incubated in a 
first reaction step with diluted patient serum 
(1:51). In the case of positive samples, specific 
antibodies of the class IgG and IgM will bind to 
the antigens. To detect the bound antibodies, a 
second incubation was carried out using an 
enzyme-labelled anti-human IgG/IgM (alkaline 
phosphatase-labelled anti-human IgG/IgM, 
goat, 10x concentrate), which is capable of 
promoting a colour reaction. Finally, a third 
incubation with substrate solution was done 
before placing the test strip on the evaluation 
protocol. This is a qualitative method: based on 
signal intensity, the results can be divided into 
negative, borderline and positive (mild, 
moderate and strong) results. Sera from 
clinically characterized patients with Guillain-
Barré syndrome (GBS) (n=71), chronic 
inflammatory demyelinating 
polyradiculoneuropathy (CIDP) (n=13), 
multifocal motor neuropathy (MMN) (n=18) and 
Miller-Fisher syndrome (MFS) (n=5), as well as 
sera from 60 healthy blood donors were 
investigated for IgG and IgM class antibodies 
against gangliosides GM1, GM2, GM3, GD1a, 
GD1b, GT1b and GQ1b. Antibodies against 
gangliosides were detected in 16 of the GBS sera 
(23%), 5 of the CIDP sera (38%), 8 of the MMN 
sera (44%) and 4 of the MFS sera (80%; 
exclusively autoantibodies of class IgG against 
GQ1b). Eleven blood donors (18%) were positive 
for IgM antibodies against GM1 (3%) or against 
GM2 (15%). Autoantibodies against the other 
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gangliosides did not occur in healthy persons (Table 1) 
 
Table 1. Prevalences of autoantibodies against gangliosides (%). Meyer W. et al., Autoinmunity reviews 1: 71 (2002) 
Patient 
group 
Ig-class GM1 GM2 GM3 GD1a GD1b GT1b GQ1b 
GBS(n=71) 
IgG 6 1 0 0 1 0 1 
IgM 13 10 1 1 3 3 1 
CIDP(n=13) 
IgG 0 0 8 0 0 0 0 
IgM 0 8 15 23 8 0 0 
MMN(n=18) 
IgG 0 6 6 0 0 0 0 
IgM 28 22 17 11 11 6 0 
GBS: Guillain-Barré Syndrome; CIDP: Chronic inflammatory demyelinating polyradiculoneuropathy; MMN: Multifocal 
motor neuropathy 
 
RESULTS 
A total of 35 patients were included (24 males, 11 females; mean 61 years).  The most frequent reason 
of ICU admission was sepsis (17/35, 48.5%), followed by pancreatitis (7/35, 20%) (Table 2). 
 
Table 2. Clinical characteristics of patients 
ID 
Age(yrs) 
/Sex(M/F) 
Reason of admittance 
Day 
Fib 
Neuromuscular 
Diagnosis 
Infection 
ICU Stay 
(d) 
MechanicalVentilation 
Time (d) 
Exitus 
51 45/M 
Hepathic 
encephalopathy 
1 CIM+CIP Unknown 12 12 YES 
20 49/M Respiratory insuficiency 2 CIM+CIP G+/G- 38 23 YES 
27 59/M Haemorrhagic shock   CIM+CIP Unknown 32 9 YES 
35 49/M Sepsis 7 CIM+CIP Fungal 41 11 YES 
42 73/M Traumatic 29 CIM+CIP None 34 34 YES 
34 71/M Pancreatitis 10 CIM G- 75 76 YES 
48 78/F Sepsis 1 CIM Unknown 13 13 YES 
46 60/M Pancreatitis 9 CIM G- 21 17 YES 
22 65/M Pancreatitis 13 CIM Virus(CMV) 32 21 YES 
23 64/F Pancreatitis 14 CIM G-(2) 52 52 YES 
37 67/F Sepsis 7 CIM G+ 14 11 NO 
44 64/M Pancreatitis 
 
CIM G+/G- 22 13 NO 
32 24/M Traumatic 32 CIM G+/G- 52 52 NO 
18 61/F Sepsis 13 CIM G+(2)/G- 66 68 NO 
16 50/F Sepsis 21 CIM G-(3) 73 66 NO 
8 72/M Sepsis 2 CIM G+ 10 9 YES 
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15 78/F Sepsis 12 CIM G+ 36 34 NO 
58 54/M Sepsis 1 CIM Unknown 29 13 YES 
59 66/F Respiratory insufficiency 1 CIM G+/G- 29 22 NO 
33 70/M Respiratory insufficiency 12 CIM G- 90 85 NO 
45 71/M Sepsis 14 CIM G- / Fungal 54 41 NO 
53 76/M Sepsis 9 CIM G-(2) 42 28 NO 
12 25/F Traumatic 12 CIM G- 21 21 NO 
57 55/M Sepsis 11 CIM Unknown 18 19 YES 
55 78/F Sepsis 5 CIM G+ 22 13 NO 
38 48/F Pancreatitis --- Normal G+ 40 7 NO 
49 46/F Graft vs host --- Normal G+ 13 9 NO 
31 59/M Sepsis --- Normal G- 14 9 NO 
40 23/M Pancreatitis --- Normal Unknown 19 17 NO 
39 77/M Sepsis --- Normal Unknown 13 8 NO 
21 71/M Sepsis --- Normal G-(3) 14 11 NO 
24 74/M Respiratory insufficiency --- Normal G+ 15 16 YES 
25 84/M Sepsis --- Normal G- 9 5 NO 
39 77/M Sepsis --- Normal Unknown 13 8 NO 
52 71/M Meningitis --- Normal G+ 14 7 NO 
 
   
Yrs: years, M: male, F: female, “Day Fib”: Days from admission until fibrillation potentials were detected in EMG study. “Infection”: Type of germen 
isolated in blood, urine or spute. G+: Gram possitive, G-: Gram negative, G+/G-: both types of germen, Virus, Fungal, Unknown or None. 
“Neuromuscular diagnosis”: CIM: Critical Illness Myopathy, CIP: Critical Illness Polyneuropathy. ICU: Intensive Care Unit 
 
In 23 patients, the first EMG abnormality 
encountered was the presence of fibrillation 
potentials. Muscle biopsy could be performed 
in 20 of them, showing typical pathological 
changes of critical illness myopathy in the 
electron microscopy examination (Figure 1). 
Two patients also exhibited histological 
features suggestive of CIM, despite fibrillation 
potentials were not detected during EMG 
studies performed during the follow-up period. 
Conversely, none of the patients with normal 
muscle biopsy presented PSA. Five patients 
were diagnosed of overlapping CIP/CIM 
according to the criteria previously stated.  
In 10 patients we did not detect any 
abnormality during the electrophysiological 
evaluation, acting as a control group. Muscle 
biopsy only was performed in two of them, 
without any type of pathological abnormality. 
Overall, mortality was 40% (14/35). Control 
group patients who survived (9/10) reached 
normal muscular strength before from those 
survivors from CIM/CIM+CIP patients group 
(13/25) (Z-score 3,8021; p<0,01) (Table 2) 
Moderate IgM reactivity against GT1b 
ganglioside was found in one patient diagnosed 
of CIM without CIP (2.8%) (Figure 2). She was a 
78 years old woman (patient number 17) who 
was admitted in ICU because of sepsis by 
staphylococcus aureus after infection of her 
knee prosthesis. CIM diagnosis was made on 
the 12th day after her admission. She required 
of mechanic ventilation for 34 days. She 
reached normal muscle strength 101 days after 
she was discharged of ICU. 
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Figure 2. Immunostaining showing GT1b anti-ganglioside reactivity 
DISCUSSION 
Antibodies against gangliosides GM1, GM2, 
GM3, GD1a, GD1b, GT1b, GQ1b are detectable 
in a reduced percentage of patients affected of 
CIM or CIM/CIP in our series. Despite all 
patients selected had a SOFA index score ≥6, 
because severity of illness has been identified as 
an independent risk factor for CIM/CIP(9), we 
only found moderate reactivity IgM against 
GT1b ganglioside in one patient diagnosed of 
CIM without CIP. GT1b is prominent in 
cultured dorsal root ganglion neurons(41) 
Reactivity against disialylated gangliosides, 
included GT1b, as well as GD1a and GM3, has 
been associated with chronic sensory ataxic 
neuropathy with relative preserved motor 
function in the limbs(42) and bulbar 
involvement, which seems to be related to 
reactivity against NeuNAc( 2-3)Gal, terminal 
epitope shared by GT1b, GM3 and GD1a 
gangliosides(43). Thus, the absence of sensory 
neuropathy assessed by EMG criteria in the 
patient with moderate reactivity against IgM 
class GT1b ganglioside antibody makes this 
finding unreliable from the pathogenic point of 
view. Furthermore, Rojas-Garcia et al. reported 
that reactivity against gangliosides containing 
disialosyl groups, in addition to antibodies 
against GM3, GD1a and GT1b, is more 
commonly found than isolated reactivity(44)   
Antibodies against ganglioside GT1b were 
detected in 3% of patients with GBS (n=71) and 
6% of patients with MMN (n=18) by means of 
the test employed in this study. They were not 
detectable in Miller-Fisher syndrome patients 
(n=5) neither in healthy blood donors (n=60). 
Nonetheless, IgM antibodies to GT1b, GM3 and 
GD2 were found in healthy volunteers during a 
study designed to determine wheter they might 
be a marker of tumor burden and predict the 
clinical outcome of patients with soft tissue 
sarcoma(44) 
Despite it should not be expected anti-
gangliosides antibodies play a primary role in 
the pathogenesis of CIM/CIP according to the 
results obtained, we have to consider two 
limitations of this study: sample size and 
method used for testing anti-ganglioside 
antibodies in sera. Enzyme-linked 
immunosorbent assay (ELISA) is the principal 
method for antibody detection. Moreover, 
standardized ELISA method between 
laboratories within the European Inflammatory 
Neuropathy Cause and Treatment (INCAT) 
group was established in order to avoid the 
wide variations between in assay performance 
between laboratories(45) However, Caudie et al. 
found anti-GT1b antibodies in 3.6% (9/249) of 
consecutive patients admitted with Guillain-
Barré syndrome by means of ELISA, similar to 
the results obtained with the test employed in 
our study.  
The involvement and failure of other organs 
and the strong association with sepsis and 
systemic inflammatory syndrome (SIRS) has 
raised the hypothesis as to whether critical 
illness polyneuropathy and myopathy is only a 
part of a systemic illness. It has been proposed 
that microcirculation disturbances and pro-
inflammatory cytokines lead to a cascade of 
electrical, bioenergetic, inflammatory and 
proteolytic pathway system alterations whose 
final consequence is the clinical, 
electrophysiological and pathological setting of 
CIP/CIM(46). Thereby, as a result of this high 
coexistence of sepsis and multiorganic failure, 
the treatment with immunoglobulin (IVIg) of 
this pathology has been debated over the last 
decade. There is some evidence that IVIg have 
survival benefit in critical ill patients with 
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sepsis(47) but over CIM/CIP there are opposing 
opinions, all of them based on open studies and 
case series(48). The results obtained in our 
prospective study do not provide evidence to 
support the use of immunoglobulin as a 
treatment for CIM/CIP. Nonetheless, we are 
cautious to raise any therapeutic conclusion 
because of our study limitations. 
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